- Home
- AGI vs RGEN Comparison
AGI vs RGEN Comparison
Compare AGI & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- RGEN
- Stock Information
- Founded
- AGI 2003
- RGEN 1981
- Country
- AGI Canada
- RGEN United States
- Employees
- AGI N/A
- RGEN N/A
- Industry
- AGI Precious Metals
- RGEN Medical/Dental Instruments
- Sector
- AGI Basic Materials
- RGEN Health Care
- Exchange
- AGI Nasdaq
- RGEN Nasdaq
- Market Cap
- AGI 7.6B
- RGEN 7.6B
- IPO Year
- AGI 1999
- RGEN N/A
- Fundamental
- Price
- AGI $18.86
- RGEN $141.76
- Analyst Decision
- AGI Strong Buy
- RGEN Buy
- Analyst Count
- AGI 5
- RGEN 11
- Target Price
- AGI $22.25
- RGEN $190.25
- AVG Volume (30 Days)
- AGI 2.5M
- RGEN 684.2K
- Earning Date
- AGI 11-06-2024
- RGEN 11-12-2024
- Dividend Yield
- AGI 0.53%
- RGEN N/A
- EPS Growth
- AGI 18.31
- RGEN N/A
- EPS
- AGI 0.60
- RGEN N/A
- Revenue
- AGI $1,225,700,000.00
- RGEN $633,513,000.00
- Revenue This Year
- AGI $30.66
- RGEN $0.44
- Revenue Next Year
- AGI $13.99
- RGEN $12.13
- P/E Ratio
- AGI $31.40
- RGEN N/A
- Revenue Growth
- AGI 22.50
- RGEN N/A
- 52 Week Low
- AGI $11.24
- RGEN $113.50
- 52 Week High
- AGI $21.45
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- AGI 45.67
- RGEN 52.33
- Support Level
- AGI $17.43
- RGEN $121.53
- Resistance Level
- AGI $18.83
- RGEN $154.48
- Average True Range (ATR)
- AGI 0.58
- RGEN 7.73
- MACD
- AGI -0.04
- RGEN -0.38
- Stochastic Oscillator
- AGI 48.31
- RGEN 61.41
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating mines in North America: Young-Davidson and Island Gold mines operate in Canada and the Mulatos and in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.